Silexion Therapeutics Corp. ( SLXN ) stock is trading higher on Thursday, with a session volume of 16.87 million compared to the average volume of 74.2 thousand as per data from Benzinga Pro.

The company released new preclinical data demonstrating that subcutaneously administered SIL204 successfully reaches all primary sites of pancreatic cancer metastasis and shows anti-tumor activity.

The study evaluated SIL204’s biodistribution and therapeutic activity following subcutaneous administration in a metastatic pancreatic cancer mouse model using bioluminescent imaging.

Also Read: Why Is Silexion Therapeutics Stock Trading Higher On Thursday?

Key Study Findings:

SIL204 was distributed to all major metastatic sites following a single subcutaneous injection at 5mg/mouse (mid-range human equivalent dose for planned clinical trials).

Reductions in bioluminescent signal, indicating decreased tumor burden, were observed at day 7 across all evaluated organs.

Statistically significant reductions (p